Evidence map›Paper›PMID 41354458›Full record

ArticleThe Journal of veterinary medical science2026

Anti-tumor effect of a histone deacetylase inhibitor on canine malignant melanoma.

Toshio Li, Hayato Shibahara, Daiki Kato, Yuka Kodera, Namiko Ikeda, Masahiro Shinada, Takaaki Iguchi, Qin Shiyu, Miki Ando, Shoma Koseki and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of veterinary medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Toshio LiLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Hayato ShibaharaLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Daiki KatoLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Yuka KoderaLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Namiko IkedaLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Masahiro ShinadaLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Takaaki IguchiLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Qin ShiyuLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Miki AndoLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Shoma KosekiLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Takahiro KakoLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Haruka MotoiLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Yuko HashimotoVeterinary Medical Center, The University of Tokyo, Tokyo, Japan.
Yosuke TakahashiVeterinary Medical Center, The University of Tokyo, Tokyo, Japan.
Ryohei NishimuraLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Takayuki NakagawaLaboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Canine malignant melanoma (CMM) is a highly aggressive tumor with limited treatment options. Histone deacetylase (HDAC) inhibitors have shown promise in cancer therapy by modulating gene expression. In this study, we investigated the anti-tumor effect of an HDAC inhibitor, vorinostat, on CMM cell lines. Vorinostat significantly suppressed cell proliferation through apoptosis and G0/G1 phase cell cycle arrest in vitro. These findings suggest that vorinostat might serve as a potential therapeutic agent for dogs with CMM, providing a basis for further in vivo studies.

Indexed as

Antineoplastic AgentsDog DiseasesHistone Deacetylase InhibitorsMelanomaAnimalsApoptosisCell Line, TumorCell ProliferationDogsVorinostatAntineoplastic AgentsHistone Deacetylase InhibitorsVorinostatdoghistone deacetylase inhibitormelanomavorinostat

Identifiers

PMID41354458
PMCPMC12887116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.